Hello dears friends.

NFT and the digital world are transforming our society – one example is through innovations like artificial intelligence (AI), augmented and virtual reality. We work together with industry leaders to test and evaluate new technologies, as well as to explore how AI and NFT can be used to create better outcomes for patients and healthcare providers. We also partner with leading companies and universities across North America to train the next generation of health IT specialists and study how the adoption of digital health services will affect patient care.

Our work is not only focused on healthcare – we're committed to making sure that AI technologies are accessible to everyone, and in so doing, improve the quality of life of citizens. For more information about our work and how we're transforming the future of health care.

International Energy Agency

The International Energy Agency (IEA) is an intergovernmental organisation with 85 member countries. The IEA promotes global sustainable development, understanding and awareness of energy, and helps countries manage energy demand and its global impacts. Through information and communication, our tools ensure energy policy makers and energy companies are equipped with the tools and information they need to make well-informed decisions. Through our workshops, publications and conferences we play a key role in raising awareness of the need to invest in energy sustainability and the role that market signals play in encouraging countries to implement sustainable development policies. For more information about our work and how we're transforming the future of energy.

And here are two organizations that aren't involved in health IT, but do have a focus on digital health:

Hutchison China MediTech

With offices in Shanghai, Beijing, Hong Kong, Mumbai, Munich, San Diego and Singapore, HCM Pharma is the first- and largest-in-Asia-to-focus on cell and gene therapies. It is driven by China's ambitions to develop its own cell and gene therapy industry. The company boasts a leadership position in China, having developed two approved cell and gene therapy products, Kymriah (tisagenlecleucel) for acute lymphoblastic leukemia and Yescarta (axicabtagene ciloleucel) for B-cell acute lymphoblastic leukemia. HCM Pharma is headquartered in Shanghai, with additional R&D and manufacturing facilities in Beijing and Tianjin. For more information about HCM's current and future pipeline.